References
1) WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/ (accessed
19/02/2021).
2) Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med
Rev 2000; 34: 75-80.
3) Katz LM. Is SARS-CoV-2 transfusion transmitted? Transfusion 2020; 1111-4.
4) Huang C, Wang Y, Xingwang L, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
5) Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens.
JAMA 2020; 323: 1843-4.
6) Zhang W, Du R-H, B ei L , e t a l. Molecular and serological investigation of 2019-nCoV infected
patients: implication of multiple shedding routes. Emerg Microbes Infect 2020; 9:386-9.
7) Chang L, Zhao L, Gong H, et al. Severe acute respiratory syndrome coronavirus 2 RNA detected in
blood donations. Emerg Infect Dis 2020; 26: 1631-3.
8) Kwon S, Kim E, Jung Y, et al. Post-donation COVID-19 identification in blood donors. Vox Sang 2020;
115: 601-2.
9) Cappy P, Candotti D, Sauvage V, et al. No evidence of SARS-CoV-2 transfusion transmission despite
RNA detection in blood donors showing symptoms after donation. Blood 2020; 136: 1888-91.
10) ECDC. Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the
EU/EEA – Second update. Available at: https://www.ecdc.europa.eu/en/publications-data/
coronavirus-disease-2019-covid-19-and-supply-substances-human-origin (accessed
19/02/2021).
11) Baron DM, Franchini M, Goobie SM, et al. Patient blood management during the COVID-19
pandemic: a narrative review. Anaesthesia 2020; 75: 1105-13.
12) Franchini M, Farrugia A, Velati C, et al. The impact of the SARS-CoV-2 outbreak on the safety and
availability of blood transfusions in Italy. Vox Sang 2020; 115: 603-5.
13) Pati I, Velati C, Mengoli C, et al. A forecasting model to estimate the drop in blood supplies during
the SARS-CoV-2 pandemic in Italy. Transfus Med 2021; in press.
SCIENTIFIC PROGRAMME
SESSION I
BONE MARROW
RESPONSE TO VIRAL
INFECTIONS
SESSION II
HAEMATOLOGICAL
RESPONSE TO SARS
COV2 INFECTION
SESSION III
DYSERYTHROPOIESIS IN
CLONAL HAEMOPOIESIS
AND MDS
SESSION IV
ERYTHROPOIESIS
CONTROL
SESSION V
ERYTHROPOIESIS
CONTROL : PHASE 2
SESSION VI
IRON METABOLISM
AND ERYTHROPOIESIS
SESSION VII
INHERITED
DYSERYTHROPOIESIS
SESSION VIII
GENE THERAPY/EDITION
SESSION IX – DRUGS
AND INEFFECTIVE
ERYTHROPOIESIS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES